Trial Profile
Evaluation of changes in trough levels (TLs) and anti-drug antibodies (ADAs) formation and disease activity after switching from originator infliximab to biosimilar infliximab in inflammatory bowel disease patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 18 Jul 2018 New trial record